Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal(Erasmus MC Cancer Institute), Hendrika M. Oosterkamp(Medisch Centrum Haaglanden), Annemiek Walenkamp(University Medical Center Groningen), Hendrikus J. Dubbink(Erasmus MC Cancer Institute), Laurens V. Beerepoot(Elisabeth-TweeSteden Ziekenhuis), Monique C.J. Hanse(Radboud University Nijmegen), Jan Buter(Amsterdam UMC Location Vrije Universiteit Amsterdam), Aafke H. Honkoop(Isala), Dolf Boerman(Rijnstate Hospital), Filip De Vos(University Medical Center Utrecht), Winand N.M. Dinjens(Erasmus MC Cancer Institute), Roelien H. Enting(University Medical Center Groningen), Martin J B Taphoorn(Medisch Centrum Haaglanden), Franchette W.P.J. van den Berkmortel(Atrium Medisch Centrum Parkstad), Rob L. H. Jansen(Maastricht University Medical Centre), Dieta Brandsma(The Netherlands Cancer Institute), Jacoline E. C. Bromberg(Erasmus MC Cancer Institute), Irene van Heuvel(Erasmus MC Cancer Institute), René M. Vernhout(Erasmus MC Cancer Institute), Bronno van der Holt(Erasmus MC Cancer Institute), Martin J. van den Bent(Erasmus MC Cancer Institute)
Cited by 751
Abstract
Related Papers
No related papers found
Powered by citation graph analysis